Literature DB >> 7536864

In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation.

P de Fabritis1, S Amadori, M C Petti, M Mancini, E Montefusco, A Picardi, T Geiser, K Campbell, B Calabretta, F Mandelli.   

Abstract

We treated a patient with chronic myeloid leukaemia in accelerated phase with autologous bone marrow transplantation. Before reinfusion, cells were purged in vitro with a 26-mer phosphorothioate antisense oligodeoxynucleotide specific for the B2A2 junction. Incubation with antisense oligodeoxynucleotides produced a 24 and 41% reduction of CFU-GM and CD34+ cells, respectively. However, an in vitro test previously performed as a screening for patient inclusion in this procedure, revealed a 38 and 75% reduction of colony formation after 24-h and 168-h incubation, respectively. The patient showed bone marrow engraftment 15 days after reinfusion and haematological reconstitution after 17 and 25 days for platelets and neutrophils, respectively. Using fluorescence in situ hybridization in interphase nuclei, we demonstrated the presence of a proportion of Ph-negative cells in repeated controls after the autograft. The patient is now in unmaintained complete haematological remission 9 months after the autograft.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536864

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  2 in total

Review 1.  Antisense cancer therapy: the state of the science.

Authors:  D M Kushner; R H Silverman
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.

Authors:  Daniela S Krause; Katherine Lazarides; Juliana B Lewis; Ulrich H von Andrian; Richard A Van Etten
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.